Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?

Larry E. Siref, Horst Zincke

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 %) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 %) had grade 3 disease or higher. Overall, in 17 (53 %) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 %) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.

Original languageEnglish (US)
Pages (from-to)309-311
Number of pages3
JournalUrology
Volume31
Issue number4
DOIs
StatePublished - Apr 1988

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint Dive into the research topics of 'Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?'. Together they form a unique fingerprint.

  • Cite this